• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Response to Stahlie et al regarding "A systematic review and meta-analysis of locoregional treatments for in-transit melanoma"

    Author(s)
    Read, Tavis
    Lonne, Michael
    Sparks, David S
    David, Michael
    Wagels, Michael
    Schaider, Helmut
    Soyer, PeterH
    Smithers, Mark B
    Griffith University Author(s)
    David, Michael
    Read, Tavis A.
    Year published
    2019
    Metadata
    Show full item record
    Abstract
    To the Editor, We wish to thank Stahlie et al1 for their interest in our article. We did not include intralesional talimogene laherparepvec (T‐VEC) therapy in our analysis as we focused on locoregional treatments available in Australia and New Zealand. However, we commend them on highlighting the promising clinical results for T‐VEC. Since completing our systematic review, four studies have been published and these underscore the value of this treatment for patients with advanced disease.2-5 Additionally, the combination of T‐VEC with systemic immunotherapies including pembrolizumab will provide further evidence concerning ...
    View more >
    To the Editor, We wish to thank Stahlie et al1 for their interest in our article. We did not include intralesional talimogene laherparepvec (T‐VEC) therapy in our analysis as we focused on locoregional treatments available in Australia and New Zealand. However, we commend them on highlighting the promising clinical results for T‐VEC. Since completing our systematic review, four studies have been published and these underscore the value of this treatment for patients with advanced disease.2-5 Additionally, the combination of T‐VEC with systemic immunotherapies including pembrolizumab will provide further evidence concerning their efficacy and safety profiles and preliminary results support this approach.6 Such combinations will also generate novel data that further define the survival outcomes of these patients.
    View less >
    Journal Title
    Journal of Surgical Oncology
    Volume
    120
    Issue
    6
    DOI
    https://doi.org/10.1002/jso.25686
    Subject
    Oncology and carcinogenesis
    Science & Technology
    Life Sciences & Biomedicine
    Surgery
    TALIMOGENE LAHERPAREPVEC
    Publication URI
    http://hdl.handle.net/10072/396613
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander